Literature DB >> 11092757

Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila.

H Y Chan1, J M Warrick, G L Gray-Board, H L Paulson, N M Bonini.   

Abstract

At least eight dominant human neurodegenerative diseases are due to the expansion of a polyglutamine within the disease proteins. This confers toxicity on the proteins and is associated with nuclear inclusion formation. Recent findings indicate that molecular chaperones can modulate polyglutamine pathogenesis, but the basis of polyglutamine toxicity and the mechanism by which chaperones suppress neurodegeneration remains unknown. In a Drosophila: disease model, we demonstrate that chaperones show substrate specificity for polyglutamine protein, as well as synergy in suppression of neurotoxicity. Our analysis also reveals that chaperones alter the solubility properties of the protein, indicating that chaperone modulation of neurodegeneration in vivo is associated with altered biochemical properties of the mutant polyglutamine protein. These findings have implications for these and other human neurodegenerative diseases associated with abnormal protein aggregation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092757     DOI: 10.1093/hmg/9.19.2811

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  112 in total

1.  Learning cell biology as a team: a project-based approach to upper-division cell biology.

Authors:  Robin Wright; James Boggs
Journal:  Cell Biol Educ       Date:  2002

Review 2.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

3.  Allele-specific silencing of dominant disease genes.

Authors:  Victor M Miller; Haibin Xia; Ginger L Marrs; Cynthia M Gouvion; Gloria Lee; Beverly L Davidson; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

4.  Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.

Authors:  Wyan-Ching Mimi Lee; Motojiro Yoshihara; J Troy Littleton
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

Review 5.  Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.

Authors:  Daniel W Neef; Alex M Jaeger; Dennis J Thiele
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

6.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

7.  Complete suppression of Htt fibrilization and disaggregation of Htt fibrils by a trimeric chaperone complex.

Authors:  Annika Scior; Alexander Buntru; Kristin Arnsburg; Anne Ast; Manuel Iburg; Katrin Juenemann; Maria Lucia Pigazzini; Barbara Mlody; Dmytro Puchkov; Josef Priller; Erich E Wanker; Alessandro Prigione; Janine Kirstein
Journal:  EMBO J       Date:  2017-12-06       Impact factor: 11.598

Review 8.  Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Human Disease.

Authors:  Tessa Sinnige; Anan Yu; Richard I Morimoto
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 9.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

10.  Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.

Authors:  Scoty M Hearst; Qingmei Shao; Mariper Lopez; Drazen Raucher; Parminder J S Vig
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.